Not a traditional drug phase: 3 days discharge for Pancreatic Neoplasms
Background: Enhanced recovery after surgery (ERAS) programs and the minimally invasive approach have significantly improved recovery outcomes following distal pancreatectomy (DP). Nevertheless, most patients stay in the hospital a median of 7 postoperative days after laparoscopic DP, despite achieving functional recovery 3-4 days earlier.
Official registry: https://clinicaltrials.gov/study/NCT07095621 · IRCCS San Raffaele · enrollment listed as 35
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 35 people at Milan. Taking part typically means a procedure as part of the study plus check-ins.
Official title (unrewritten)
Feasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy
Interventions: 3 days discharge
Primary outcome (registry wording): Percentage of patients without any Emergency Department (ED) visits within POD7
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- adult (age\>= 18 years) patients undergoing elective minimally invasive distal pancreatectomy
- patients residing or with a temporary accommodation within 50 km or a 30-minute drive from the hospital;
- patients with an adequate support system at home (defined as 24-hour support for at least the first POD7);
- no contraindications to intrathecal or opioid-sparing analgesia;
- patient who have signed the inform consent for participation in the trail;
- No preoperative medical issue requiring inhospital observation longer than three days
Who the registry excludes
- Patients undergoing multi-visceral resection;
- undergoing an open procedure;
- requiring vascular resection;
- having a history of chronic opioid use;
- having significant comorbidities or an American Society of Anesthesiologists (ASA) score \> 3;
- patients unabled to speak Italian;
- having a cognitive impairment;
Public study contact (from the registry)
Nicolò Pecorelli, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- IRCCS Ospedale San Raffaele — Milan, Italy (recruiting)
FAQ about this NCT record
Is NCT07095621 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07095621?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07095621?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary